Neo-Bioscore staging system adds HER2 status for precise prognostic stratification of

[News]

A new breast cancer staging system developed by researchers at The University of Texas MD Anderson Cancer Center finds that incorporating tumor biology is a critical prognostic indicator for women who undergo neoadjuvant, or pre-surgical, therapy for breast cancer.

More... (http://www.news-medical.net/news/20160318/Neo-Bioscore-staging-system-adds-HER2-status-for-precise-prognostic-stratification-of-breast-cancer-subtypes.aspx)